Plasma lipolytic activity and substrate oxidation after intravenous administration of heparin and a low molecular weight heparin fragment.
This study examines the effects of heparin and a low molecular weight heparin (LMWH) fragment on plasma lipolytic activity and substrate oxidation. Indirect calorimetry was performed continuously in healthy male subjects receiving a constant infusion of fat emulsion (0.2 g min-1) and glucose (0.8 g min-1) during a period of 4 h. After 2 h an infusion of heparin (n = 6) or LMWH (n = 6) (100 antifactor Xa units kg-1) or saline (n = 6) was given over 1 h. Plasma concentration of the fat emulsion decreased by 76 +/- 5% with heparin and by 12 +/- 7% with LMWH (P less than 0.01). In the case of LMWH the initial fall was followed by a consistent rise in fat emulsion concentration for the entire remaining study period. Compared to the control experiments, plasma FFA increased five times with heparin and three times with LMWH (P less than 0.05). The average respiratory quotient (RQ) and energy expenditure (EE) increased constantly during the study period and did not differ significantly between the groups. In all groups the average increase in glucose oxidation was 40-50%, while fat oxidation decreased to a comparable extent. Infusions of heparin and LMWH had no effect on RQ or EE. A microcalorimetric study on isolated rat adipocytes in buffer solutions containing glucose, fat emulsion, heparin or LMWH was also made. The heat output from the adipocytes was not influenced by the presence of heparin or LMWH. In conclusion, infusion of heparin resulted in a pronounced increase in FFA availability, whereas LMWH exerted a less marked lipolytic effect. However, the heparin-induced elevations in plasma FFA were not accompanied by measurable rises in lipid oxidation rate.
Persson
E
E
Department of Anaesthesia, Karolinska Hospital, Stockholm, Sweden.
Nordenström
J
J
Nilsson-Ehle
P
P
Hagenfeldt
L
L
Wahren
J
J
D000328:Adult; D000818:Animals; D002151:Calorimetry; D005217:Fat Emulsions, Intravenous / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D008049:Lipase / Q000096:biosynthesis; D008066:Lipolysis / Q000187:drug effects*; D008071:Lipoprotein Lipase / Q000096:biosynthesis; D008297:Male; D010084:Oxidation-Reduction / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012119:Respiration / Q000187:drug effects
D005217:Fat Emulsions, Intravenous; D005227:Fatty Acids; D006495:Heparin, Low-Molecular-Weight; D007328:Insulin; D006493:Heparin; D008049:Lipase; D008071:Lipoprotein Lipase; D005947:Glucose